Clinical Trial Update: Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir [Phase 2]

View source ↗

Summary

A Phase 2 dose-response trial of tipranavir in a self-emulsifying drug delivery system in treatment-naive HIV-1 infected patients, including a post-study option…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Delavirdine (delavirdine)
• Lamivudine (Epivir) (lamivudine)
• Tipranavir (Aptivus) (tipranavir)
• Zidovudine (Retrovir) (zidovudine)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections | Phase 2 | Status: COMPLETED